Posted by Clinical Lab Products | Oct 27, 2010 | Cancer, Miscellaneous |
Men treated for prostate cancer who were diagnosed after the start of routine screening had a significantly reduced risk of the disease spreading to other parts of the body within 10 years of treatment.
Read MorePosted by Clinical Lab Products | Oct 25, 2010 | Cancer, Miscellaneous |
GE Healthcare, a unit of General Electric Company, and Clarient Inc announced have entered into a definitive agreement for GE Healthcare to acquire Clarient.
Read MorePosted by Clinical Lab Products | Sep 23, 2010 | Cancer, Miscellaneous |
Gen-Probe announced that the Company has submitted a Premarket Approval Application (PMA) to the FDA for its PROGENSA PCA3 assay.
Read MorePosted by Clinical Lab Products | Sep 16, 2010 | Cancer, Miscellaneous |
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden.
Read MorePosted by Clinical Lab Products | Sep 13, 2010 | Cancer, Miscellaneous |
Experts at The University of Texas MD Anderson Cancer Center advise men to keep a record of their prostate specific antigen (PSA) test results to help determine if they are at increased risk for prostate cancer.
Read More